Nexalin Technology (NXL) Stock: Buy, Sell, or Hold?
NXL - Nexalin Technology, Inc. Common Stock
$1.86
-0.17 (-8.37%)
▼
5d:
-20.85%
30d:
-57.29%
90d:
+320.81%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 13, 2026
20d
Get Alerted When NXL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NXL is down 20.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NXL is down 20.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NXL is currently trading at $1.86, which is considered oversold relative to its 30-day fair value range of $2.65 to $5.29.
Technical Outlook: Technically, NXL is in a strong downtrend. The price is currently testing key support at $1.86. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: NXL scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $15.00 (+638.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NXL is in a strong downtrend. The price is currently testing key support at $1.86. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: NXL scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $15.00 (+638.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.65 -
$5.29
Company Quality Score
52/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
84.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BEARISH: Downward momentum (-8.4%)
- BULLISH: Trading 638.9% below Wall St target ($15.00)
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.65 -
$5.29
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.86
Resistance Level
$3.76
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.27
Wall Street Target
$15.00
(+638.9%)
Revenue Growth (YoY)
-82.8%
Share & Embed Analysis
Last updated: October 23, 2026 4:53 PM ET
Data refreshes hourly during market hours. Next update: 5:53 PM
Data refreshes hourly during market hours. Next update: 5:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NXL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
EW
Edwards Lifesciences Corp |
STRONG BUY
29 analysts |
$102 | 58 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
29 analysts |
$96 | 46 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
28 analysts |
$121 | 52 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
29 analysts |
$363 | 37 SELL |
|
CATX
Perspective Therapeutics… |
STRONG BUY
14 analysts |
$12 | 56 HOLD |
